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716Objective: Respiratory failure develops in many patients on lung transplant waiting lists before a suitable donor
organ becomes available. Extracorporeal membrane oxygenation may be used to bridge such patients to recov-
ery or lung transplantation.
Methods: This is a review of a single-institution’s experience with placing patients on extracorporeal membrane
oxygenation with the intention of bridging them to lung transplantation. End points included successful bridg-
ing, duration of extracorporeal membrane oxygenation support, extubation, weaning from extracorporeal mem-
brane oxygenation, overall survival, and extracorporeal membrane oxygenation–related complications. During
an approximate 5-year period, acute respiratory failure developed in 18 patients (median age, 34 years) on the
institution’s lung transplant waiting list (8 hypoxemic, 9 hypercarbic, and 1 combined) who were placed on ex-
tracorporeal membrane oxygenation (13 venovenous and 5 venoarterial).
Results: All patients achieved appropriate extracorporeal membrane oxygenation blood flow rates (median,
4.05 L/min) and good gas exchange (median, on extracorporeal membrane oxygenation partial pressure of
arterial carbon dioxide 43 mm Hg and partial pressure of arterial oxygen 196 mm Hg). Thirteen patients
(72%) were successfully bridged: 10 to transplant and 3 returned to baseline function. Eleven patients
(61%) survived beyond 3 months, including the 10 (56%) who underwent transplantation and are still alive.
The median duration of extracorporeal membrane oxygenation support for patients who underwent trans-
plantation was 6 days (3.5-31 days) versus 13.5 days (11-19 days) for those who did not undergo transplan-
tation (P ¼ .45). Six patients (33%) were extubated on extracorporeal membrane oxygenation, 4 of whom
underwent transplantation. Four patients (22%) who were too unstable for conventional interhospital trans-
fer were transported on extracorporeal membrane oxygenation to Columbia University Medical Center. This
subgroup had a 75% bridge to transplant or recovery rate and 100% survival in transplanted patients.
Conclusions: Extracorporeal membrane oxygenation is a safe and effective means of bridging well-selected pa-
tients with refractory respiratory failure to lung transplantation or return to their baseline condition. (J Thorac
Cardiovasc Surg 2012;144:716-21)Given the 12- to 24-month waiting period, patients with
end-stage lung disease can acutely decompensate and de-
velop refractory respiratory failure before suitable donor
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The Journal of Thoracic and Cardiovascular Surgmechanical ventilation may render these patients unsuitable
for transplantation.
Patients with respiratory failure requiring mechanical
ventilation can be temporarily supported on extracorporeal
membrane oxygenation (ECMO) while they wait for a lung
transplant if mechanical ventilation alone is insufficient to
meet their gas exchange needs.2,3 ECMO may even allow
some patients to be removed from mechanical ventilation
while they await transplantation, which permits patients to
eat, to participate in their own care, and to work more
extensively with physical therapists, including ambulating
with assistance. This has the potential to improve their
pretransplant conditioning during this critical illness
phase rather than allowing it to worsen, which is typically
the case in these patients.
Venovenous ECMO is often sufficient to support such
patients’ physiologic needs. However, when there is signif-
icant pulmonary hypertension, an acute exacerbation can
lead to right-sided heart failure that benefits from the ven-
tricular unloading afforded by venoarterial ECMO.ery c September 2012
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
IQR ¼ interquartile range
PaO2 ¼ partial pressure of arterial oxygen
PaCO2 ¼ partial pressure of arterial carbon dioxide
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XTo date, the routine use of modern mechanical circulatory
support to bridge patients to lung transplantation has been
limited.4 The paucity of experience in the literature has pre-
vented any durable conclusions regarding the safety and ef-
ficacy of such a strategy. Most previous reports have been
limited by the use of multiple extracorporeal life support
techniques, outdated technology, and small sample size.5,6
We report on the use of contemporary ECMO technology
and management strategies to bridge patients listed for lung
transplantation who subsequently developed an acute exac-
erbation of their underlying respiratory failure requiring in-
vasive mechanical ventilation.
PATIENTS AND METHODS
This study, which was approved by the Columbia University Medical
Center Institutional Review Board, is a retrospective review of a single in-
stitution’s experience with bridging patients on the active lung transplant
list to transplantation or recovery using ECMO support.
Patient Selection
The decision to place patients on ECMOwas made by a team composed
of thoracic surgeons, critical care intensivists, and transplant pulmonolo-
gists. To be a bridge candidate, a patient needed to be on the institution’s
active lung transplant waiting list. The indications for considering
ECMO support were the presence of hypoxemic or hypercarbic respiratory
failure requiring invasive mechanical ventilation with high levels of sup-
port or worsening right-sided heart failure.7 The lung diseases associated
with hypoxemic respiratory failure included exacerbation of interstitial
pulmonary fibrosis and pulmonary hypertensive crisis due to a congenital
heart defect. In these patients, a partial pressure of arterial oxygen tension
(PaO2) to inspired oxygen fraction less than 80 was needed before initiation
of ECMO. Hypercarbic respiratory failure (uncompensated hypercapnia
with acidosis, pH< 7.25 despite optimal ventilator management) was
seen in patients with an exacerbation of cystic fibrosis.
Patients who acquired a known contraindication to continuing ECMO
support were decannulated. If a suitable donor lung was immediately avail-
able, patients were considered for transplant. Otherwise, the patient was de-
listed if temporarily maintaining the patient with mechanical ventilation
alone was not feasible. Criteria for delisting a patient, whether temporarily
or permanently, were consistent with institutional and United Network for
Organ Sharing guidelines for all patients on the lung transplant waiting list.
This included delisting patients who contracted and could not resolveClos-
tridium difficile colitis or who developed multiorgan system dysfunction
while on ECMO. The institutional lung transplant selection committee
made listing decisions. The transplant pulmonologists and cardiothoracic
surgeons used the institution’s standardized donor lung evaluation protocol
to evaluate donor lungs for patients on ECMO.
Protocol
The cannulation techniques used were specific to the ECMO configura-
tion deemed by the ECMO team to best serve the patient’s physiologicThe Journal of Thoracic and Caneeds. Patients were placed on venovenous ECMO via the internal jugular
vein or venoarterial ECMO via femoral or subclavian arteries using previ-
ously described techniques.8,9 Patients with a congenital heart defect had
the right internal jugular vein cannulated with a bicaval dual-lumen can-
nula under transesophageal echocardiographic guidance according to a pre-
viously described technique.10 The cannulae were attached to
a standardized circuit. The ECMO circuit consisted of a Quadrox D or
Quadrox I oxygenator (Maquet Inc, Rastatt, Germany) and a Jostra Rota-
flow (Maquet Inc) or Levitronix Centrimag (Levitronix, GmbH, Zurich,
Switzerland) centrifugal pump.
If patients on Columbia University Medical Center’s lung transplant list
decompensated at an outside hospital and were thought to be appropriate
bridge to transplant candidates, theywere cannulated at the outside hospital
and transported via a mobile ECMO unit per standardized protocol.11 All
patients were managed on ECMO according to a low-dose anticoagulation
protocol (a partial thromboplastin time of 40-60 seconds). Therewas a high
threshold for blood product transfusion with the goal of minimizing the cre-
ation of future antibodies, especially if a delay in transplantation was ex-
pected.12,13 Leukocyte-depleted packed red blood cells were used for
transfusion. Patients did not receive a transfusion unless it was needed to
meet physiologic demand.
A review of the clinical records was conducted to obtain information re-
garding the patient’s pre-ECMO status, operative course, hospitalization,
and intensive care unit (ICU) stay. End points included successful bridging,
duration of ECMO support, extubation, weaning from ECMO, overall sur-
vival, and ECMO-related complications.Statistical Methods
All statistical analyses were performed with a statistical package (Stata
11; StataCorp LP, College Station, Tex). The total median ICU stay con-
sisted of pre-ECMO, on-ECMO, and post-transplant ICU stays. Median
values were provided with interquartile ranges (IQRs). To minimize poten-
tial concerns regarding normality of the data distribution, nonparametric
rank-sum tests were used to compare continuous variables where appropri-
ate. Categoric variables were compared using chi-square tests. The Wil-
coxon Mann–Whitney rank-sum test, Fisher exact test, and univariate
logistic regression were used for comparisons and subgroup analysis. A
successful bridge was defined as any patient on the lung transplant waiting
list who underwent transplantation or recovered after being placed on
ECMO. Survival comparisons were made with Kaplan–Meier analysis,
with survival estimates compared using a log-rank test. Overall survival
was defined as the time from placement on ECMO to death or last
follow-up through April 15, 2012. For the purpose of assessing statistical
significance, a conventional alpha of 0.05 was used.Demographics
From July 2007 to April 2012, 18 patients on the lung transplant list who
experienced acute respiratory failure requiring invasive mechanical venti-
lation were placed on ECMO as a bridge to transplantation. This represents
less than 10% of the total patients placed on ECMO during this period and
is the entire institutional experience with bridging patients to lung trans-
plantation using ECMO.
Nine patients experienced hypercarbic respiratory failure with a median
pre-ECMOpH of 7.17 andmedian partial pressure of carbon dioxide of 123
mmHg. One patient had combined hypercarbic and hypoxemic respiratory
failure. The remaining 8 patients had hypoxemic respiratory failure with
PaO2 to fraction of inspired oxygen of 63 (Table 1). The patients with pul-
monary hypertensive crises had systemic or suprasystemic pulmonary ar-
tery pressures and right ventricular failure confirmed on transthoracic or
transesophageal echocardiography.
The majority of patients (72%) were supported for the entire extracor-
poreal life support course on venovenous ECMO. Five patients required ve-
noarterial ECMO support. One patient was placed on femoral venoarterialrdiovascular Surgery c Volume 144, Number 3 717
TABLE 1. Study population characteristics
Variables* Types of respiratory failure
Overall P valueDemographics Hypercarbic Hypoxic Combined
Study population 9 (50%) 8 (44%) 1 (6%) 18
Age, y 33 (21-42) 46 (28-61) 18 34 (22-50) .16
BMI 23 (19-25) 22 (17-27) 16 22 (19-25) .67
Sex .06
Male 2 6 0 8
Female 7 2 1 10
Pretransplant lung allocation score 93 (90-94) 94 (81-94) 95 93 (90-94) .77
Reason for ECMO support
Cystic fibrosis exacerbation 8 8
Interstitial pulmonary fibrosis exacerbation 6 6
Congenital atrial septal defect with pulmonary
hypertension and right ventricular failure
2 2
Respiratory variables
Pre-ECMO
PaO2/FIO2 200 (74-228) 63 (58-71) 63 74 (63-200) <.01
pH 7.17 (7.10-7.19) 7.36 (7.07-7.43) 7.17 7.26 (7.16-7.37) .56
PCO2, mm Hg 123 (86-140) 52 (41-115) 93 99 (52-130) .06
PaO2, mm Hg 119 (74-200) 63 (55-73) 63 74 (64-158) <.01
SaO2,% 96 (92-97) 89 (78-92) 88 92 (89-97) .02
On-ECMO
pH 7.48 (7.43-7.49) 7.44 (7.43-7.48) 7.48 7.48 (7.43-7.48) .45
PaCO2, mm Hg 47 (43-56) 40 (32-43) 55 43 (40-49) .01
PaO2, mm Hg 241 (137-335) 196 (108-348) 109 196 (109-335) .96
SaO2,% 100 (99-100) 99.7 (98-100) 99 100 (99-100) .45
Cannulation strategy
Venovenous
Single-site (internal jugular vein) 7 4 11 —
Dual-site (internal jugular and femoral vein) 2 2 —
Venoarterial
Subclavian artery and internal jugular vein 1 1 2 —
Femoral artery and vein 1 1 —
Femoral artery and internal jugular veiny 1 1 2 —
BMI, Body mass index; ECMO, extracorporeal membrane oxygenation; PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired oxygen; PaCO2, partial pressure of
arterial carbon dioxide; SaO2, arterial oxygen saturation. *Data are presented as number or median (IQR). yConversion from venovenous to venoarterial ECMO.
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XECMO because a venogram showed superior vena caval stenosis, which
prohibited accommodation of a large venovenous ECMO catheter. Two pa-
tients had pulmonary hypertension with severe right-sided heart failure and
were cannulated via the right subclavian artery. Two patients did not toler-
ate venovenous ECMO, as was evidenced by low cardiac output and persis-
tent pressor requirements without improvement in end-organ oxygenation.
These patients were transitioned to femoral venoarterial ECMO (Table 1).
RESULTS
The median duration of pre-ECMO mechanical ventila-
tion was 18 hours (IQR, 12-24 hours). All patients under-
went successful cannulation and were able to achieve
appropriate blood flow rates for their catheter size (me-
dian, 4.05 L/min) and suitable gas exchange (on-ECMO
partial pressure of carbon dioxide 43 mm Hg and PaO2
196 mm Hg). Four patients (22%) were cannulated at
an outside hospital and transported without any adverse
events to Columbia University Medical Center while re-
ceiving ECMO.718 The Journal of Thoracic and Cardiovascular SurgThe median duration of ECMO support was 11.5 days
(IQR, 6-18 days). The median duration of ECMO support
for those who underwent transplantation was 6 days (IQR,
4-18 days) versus 13.5 days (IQR, 11-19 days) for patients
who did not undergo transplantation (P ¼ .45). One pa-
tient received double lung transplant after being bridged
for 31 days on ECMO. Six patients (33%) did not require
a blood transfusion during their entire run on ECMO
(Table 2). The total median ICU length of stay was 20
days (IQR, 16-32 days). The ICU stay was longer in the
subgroup that underwent transplantation (22 vs 16.5
days for the group that did not undergo transplantation,
P ¼ .35). The median hospital length of stay was 36.5
days (22-51 days); however, it was shorter in the group
that did not undergo transplantation (22.5 vs 47 days for
the group that underwent transplantation) (P ¼ .07)
(Table 2). This was attributable to the higher mortality
in the group that did not undergo transplantation.ery c September 2012
TABLE 2. Extracorporeal membrane oxygenation performance parameters
Variable*
Successful bridge
Failed bridge OverallTransplantation Returned to baseline functionz
No. 10 3 5 18
ECMO flow rate, L/min 4.05 (3.3-4.5) 3.9 (3.25-4.3) 4.20 (3.5-4.4) 4.05 (3.7-4.4)
Incidence of transfusion 5 2 3 10 (56%)
pRBC transfused, unitsy 0.16 (0-0.17) 0.27 (0-0.30) 0.16 (0.07-0.26) 0.16 (0-0.25)
Platelets transfused, mLy 0 0 (0-28) 0 (0-5) 0
Duration of ECMO, d 6 (3.5-18) 11 (2-23) 15 (12-17) 11.5 (6-18)
ICU length of stay, d 22 (18-33) 16 (14-94) 17 (16-23) 20 (16-32)
Hospital length of stay, d 47 (41-52) 22 (16-178) 23 (16-28) 36.5 (22-51)
ECMO, Extracorporeal membrane oxygenation; pRBC, packed red blood cells; ICU, intensive care unit. *Data are presented as number or median (IQR). yPer day on ECMO.
zPatient recovered from acute decompensation and was extubated.
TABLE 3. Study population outcomes
Variable No. Range or%
ECMO results 18 100
Mechanical ventilator pre-ECMO, h 18 (12-24)*
Duration of ECMO support, d 11.5 (6-18)
Successful wean from ECMO/decannulated 17 94
Liberation from mechanical ventilation 13 72
Liberation from mechanical ventilation while on
ECMO
6 33
Successful bridgey 13 72
Bridge to transplant 10 56
Bridge to recovery/baseline function 3 17
Ambulation on ECMO 5 28
Bike riding on ECMO 2 11
Survival and follow-up
Died while on ECMO 1 6
Died after decannulation from ECMO 5 28
Discharged from ICU 13 72
Discharged from hospital 11 61
Severe primary graft failure (N¼ 10 transplanted) 2 20z
Survival
1 mo 12 67
Bridged to transplantx
1 mo (N ¼ 10, at risk)x 10 100
6 mo (N ¼ 7, at risk) 7 100
1 y (N ¼ 6, at risk) 6 100
2 y (N ¼ 3, at risk) 3 100
Overall survival in subgroup that underwent
transplantation
10 100
ECMO-related complications
Heparin-induced thrombocytopenia 1 6
Deep venous thrombosis at cannulation site 1 6
Conversion to venoarterial ECMO 2 11
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit. *Interquar-
tile range. yReceived transplant or recovered to baseline function. zOf subgroup.
xBridged to transplant only.
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mechanical ventilation after recovering to their baseline or
being successfully bridged to transplant. Ten patients
(56%) underwent transplantation (8 double and 2 single
lung transplants), and all are alive to date. This represents
4% of the approximately 250 total lung transplants per-
formed during the duration of the study period at Columbia
UniversityMedical Center. Severe primary graft dysfunction
developed in 2 patients who underwent transplantation, and
they required a second course of venovenous ECMO. All
patients currently have a viable, functioning graft (Table 3).
Eight patients (44%) died, none of whom received trans-
plants. This includes the 3 patients who transiently recov-
ered their baseline function and were extubated after
being weaned from ECMO. One patient survived beyond
3 months. Two patients were delisted after decannulation
and were extubated. One patient survived 2 weeks, and 1
patient survived 2 months. The causes of mortality were
multisystem organ failure (n ¼ 6), pneumonia (n ¼ 1),
and sudden cardiac arrest (n¼ 1). ECMO-related complica-
tions included a deep venous thrombosis that resolved with
anticoagulation after transplantation and suspected heparin-
induced thrombocytopenia requiring Argatroban (Glaxo-
SmithKline, Middlesex, UK) (Table 3).
DISCUSSION
This series examines a high-volume ECMO center’s expe-
rience with using peripheral extracorporeal support as
ameans of bridging patients to lung transplant or recovery af-
ter an episode of acute respiratory failure. This experience re-
inforces other studies performed at centers in the United
States and Europe.2,14 Other means of bridging patients
with end-stage lung disease, including the Novalung
(Novalung GmbH, Heilbronn, Germany) interventional
lung assist device or percutaneous extracorporeal carbon
dioxide exchange, have notable disadvantages, such as
femoral access and inability to provide complete
respiratory support, respectively.15,16 Accordingly, centers
have moved away from these technologies when bridging
patients to lung transplant.The Journal of Thoracic and CaVenovenous ECMO is our center’s preferred approach for
bridging patients to lung transplantation because it avoids
the potential complications associated with the arterial can-
nula, such as limb ischemia, and can often be accomplished
through a single peripheral cannula. However, 1 patient withrdiovascular Surgery c Volume 144, Number 3 719
FIGURE 1. The 6 patients who were extubated while on ECMO participated in physical therapy and activities of daily living before undergoing transplan-
tation. This patient on ECMO is (A) using her cellular telephone and laptop computer and (B) performing arm-strengthening exercises with the physical
therapist.
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venovenous ECMOandwas converted to peripheral venoar-
terial ECMO.
Upper-body ECMO cannulation (via the internal jugular
vein and subclavian artery—when venoarterial ECMO is
needed) facilitates patient mobilization and participation
in physical therapy.13 Six patients were extubated while
on ECMO. Five patients ambulated around the ICU, and 2
patients rode an upright stationary bike. During ambulation,
patients used a rolling walker while a streamlined ECMO
circuit (pump, oxygenator, and oxygen source) on a roller
chart followed in tow. Early patient mobilization while on
ECMO minimizes physical deconditioning, which allows
the patient to better tolerate lung transplantation (Figure 1).
In addition to early mobilization, patients are able to eat
and drink normally and participate in ongoing counseling,
which helps them better handle the psychologic rigors and
stresses of both the bridge period and the immediate post-
transplant phase.17 The combined benefits of extubating
and ambulating patients on ECMOmay offset any potential
drawbacks of a prolonged bridge period. These steps may
actually improve patients’ suitability for lung transplant
during the course of their critical illness. Likewise, a con-
scious effort to minimize transfusions during the ECMO pe-
riod may reduce the risk of antibody generation, although
such an effect is likely small given the time frame required
to develop antibodies relative to the waiting time for donor
lungs.
The combination of transporting patients on ECMO and
bridging them to lung transplantation was found to be a safe
and effective means of bringing patients to an experienced
transplant center. This is especially important because
lung transplantation is typically limited to major medical
centers that are often located in urban areas. Therefore,720 The Journal of Thoracic and Cardiovascular SurgECMO technology can expand treatment options for pa-
tients who live in remote areas. This concept has been
shown to be feasible in select centers in Europe.2
The cause of respiratory failure did not affect rates of
decannulation, extubation, transplantation, or overall sur-
vival. The duration of pre-ECMO mechanical ventilator
support was brief, but this can be attributed to the fact
that the patients rapidly decompensated, as seen in the
pre-ECMO arterial blood gas, and did not tolerate maximal
conventional respiratory support.
Patients tolerated prolonged periods of time (up to 1
month) on ECMO and were still deemed suitable transplant
candidates.4,18 However, bridging a patient on ECMO is
not an indefinite process. Once patients were deemed to no
longer be transplant candidates, they were delisted and
weaned from ECMO. Strict patient selection in terms of
transplantation may have contributed to superior early
results in the population who underwent transplantation.4
Patients who underwent transplantation were all dis-
charged from the hospital and have a 100% survival
through July 1, 2012 (Figure 2). In this exploratory analysis,
the survival figures for the population of lung transplant re-
cipients bridged on ECMO are not inferior to other trans-
plant recipients given the median lung allocation score of
93. Comparatively, on the basis of an analysis of United
Network for Organ Sharing data, lung transplant recipients
with a lung allocation score greater than 90 have a 50% sur-
vival at 2 years.19 Longer follow-up and more patients are
needed to validate our preliminary clinical experience.
This study was further limited by its single-institution,
retrospective nature. Although attempting to bridge 18 pa-
tients to transplantation over an approximately 5-year pe-
riod was a relatively substantial experience, the study was
inadequately powered to discern significant differences atery c September 2012
FIGURE 2. Survival in patients bridged on ECMO to lung transplantation
or recovery. ECMO, Extracorporeal membrane oxygenation.
Javidfar et al Cardiothoracic Transplantationthe subgroup level. A multicenter, prospective randomized
study would likely elucidate these differences.CONCLUSIONS
ECMO is a feasible, safe, and effective means of bridging
patients to transplantation who develop an exacerbation of
their end-stage lung disease resulting in acute respiratory
failure. ECMO offers promise to patients who might other-
wise die before suitable donor lungs become available.References
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